VigiEye

Regulatory · Clinical trials · Pharmacovigilance · Quality · Market access, for EU & US pharma, from the official sources

Monday 16 November 2026
RegulatoryCompany release

FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia

Noema Pharma's oral mGluR5 modulator, already on the FDA's Fast Track, now also carries orphan status for the rare and painful neuropathic condition.

Noema Pharma AG · Mon 16 Nov 2026
Pulse: the last two weeksEU calendar →
Analysis & opinionAll analysis →
PharmacovigilanceMore Pharmacovigilance →
Clinical trialsMore Clinical trials →
Quality & complianceMore Quality & compliance →
New guidelines: ICH, FDA, EMA, MHRAGuidelines tracker →
More newsAll news →

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.